In a phase Ib clinical trial of patients with selected advanced solid tumors, combination of the pan-PI3K inhibitor BKM120 and the MEK1/2 inhibitor trametinib displayed promising anti-tumor activities to patients with KRAS-mutant ovarian cancer [25]. This evidence concerns the gene MAP2K1 and neoplasm.